This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baselga, J. Search for Related Content PubMed PubMed Citation Articles by Baselga, J.

Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy

Medical Oncology Service, Hospital Universitari Vall d’Hebron, Barcelona, Spain

Correspondence: José Baselga, M.D., Medical Oncology Service, Hospital General Universitari Vall d’Hebron, Paseo Vall d’Hebron 119-129, 08035 Barcelona, Spain. Telephone: 34-93-274-6077; Fax: 34-93-274-6059; e-mail: baselga{at}hg.vhebron.es

There is a need for new, selective anticancer agents that differentiate between malignant and nonmalignant cells. The benefits of such agents would include a higher therapeutic index and lower toxicity than conventional therapies. Although expressed in nonmalignant cells, the epidermal growth factor receptor (EGFR) is highly expressed in a variety of tumors, and its expression correlates with poor response to treatment, disease progression, and poor survival. Evidence for a role for the EGFR in the inhibition and pathogenesis of various cancers has led to the rational design and development of agents that selectively target this receptor. Activation of the EGFR signaling pathway in cancer cells has been linked with increased cell proliferation, angiogenesis, and metastasis, and decreased apoptosis. Preclinical data show that anti-EGFR therapies can inhibit these effects in vitro and in vivo. In addition, preclinical data confirm that many such agents have the potential to increase the effectiveness of current cytotoxic agents. Following accelerated drug development programs, phase III trials are now under way for a number of EGFR-targeted therapies, including the monoclonal antibody IMC-C225 and the EGFR-tyrosine kinase inhibitors ZD1839 (Iressa^TM) and OSI-774. Thus, the rationale for EGFR-targeted approaches to cancer treatment is apparent and now well established, and there is increasing evidence that they may represent a significant contribution to cancer therapy.

Key Words. EGFR • Monoclonal antibodies • EGFR-TKIs • ZD1839 (Iressa^TM)

This article has been cited by other articles:

				S. Adachi, M. Shimizu, Y. Shirakami, J. Yamauchi, H. Natsume, R. Matsushima-Nishiwaki, S. To, I.B. Weinstein, H. Moriwaki, and O. Kozawa (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells Carcinogenesis, September 1, 2009; 30(9): 1544 - 1552. [Abstract] [Full Text] [PDF]

				D. J. Freeman, T. Bush, S. Ogbagabriel, B. Belmontes, T. Juan, C. Plewa, G. Van, C. Johnson, and R. Radinsky Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor Mol. Cancer Ther., June 1, 2009; 8(6): 1536 - 1546. [Abstract] [Full Text] [PDF]

				E. Eiling, M. Brandt, T. Schwarz, and A. Hauschild Pimecrolimus: A Novel Treatment for Cetuximab-Induced Papulopustular Eruption Arch Dermatol, September 1, 2008; 144(9): 1236 - 1238. [Full Text] [PDF]

				G. L. Bentz and A. D. Yurochko Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and {beta}1 and {beta}3 integrins PNAS, April 8, 2008; 105(14): 5531 - 5536. [Abstract] [Full Text] [PDF]

				A. Pivarcsi, A. Muller, A. Hippe, J. Rieker, A. van Lierop, M. Steinhoff, S. Seeliger, R. Kubitza, U. Pippirs, S. Meller, et al. Tumor immune escape by the loss of homeostatic chemokine expression PNAS, November 27, 2007; 104(48): 19055 - 19060. [Abstract] [Full Text] [PDF]

				K. J. Hare, B. Hartmann, H. Kissow, J. J. Holst, and S. S. Poulsen The Intestinotrophic Peptide, GLP-2, Counteracts Intestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Gefitinib Clin. Cancer Res., September 1, 2007; 13(17): 5170 - 5175. [Abstract] [Full Text] [PDF]

				W. S. Siegel-Lakhai, J. H. Beijnen, W. L. Vervenne, H. Boot, M. Keessen, M. Versola, K. M. Koch, D. A. Smith, L. Pandite, D. J. Richel, et al. Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors Clin. Cancer Res., August 1, 2007; 13(15): 4495 - 4502. [Abstract] [Full Text] [PDF]

				B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]

				I. R Hutcheson, J. M Knowlden, H. E Jones, R. S Burmi, R. A McClelland, D. Barrow, J. M W Gee, and R. I Nicholson Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S89 - S97. [Abstract] [Full Text] [PDF]

				T. W. Wong, F. Y. Lee, C. Yu, F. R. Luo, S. Oppenheimer, H. Zhang, R. A. Smykla, H. Mastalerz, B. E. Fink, J. T. Hunt, et al. Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling. Clin. Cancer Res., October 15, 2006; 12(20): 6186 - 6193. [Abstract] [Full Text] [PDF]

				B. Vincenzi, D. Santini, and G. Tonini New Issues on Cetuximab Mechanism of Action in Epidermal Growth Factor Receptor-Negative Colorectal Cancer: The Role of Vascular Endothelial Growth Factor J. Clin. Oncol., April 20, 2006; 24(12): 1957 - 1957. [Full Text] [PDF]

				D. Vitolo, L. Ciocci, G. Deriu, S. Spinelli, S. Cortese, L. Masuelli, S. Morrone, M. J. Filice, G. F. Coloni, P. G. Natali, et al. Laminin {alpha}2 Chain-Positive Vessels and Epidermal Growth Factor in Lung Neuroendocrine Carcinoma: A Model of a Novel Cooperative Role of Laminin-2 and Epidermal Growth Factor in Vessel Neoplastic Invasion and Metastasis Am. J. Pathol., March 1, 2006; 168(3): 991 - 1003. [Abstract] [Full Text] [PDF]

				U. Reusch, M. Sundaram, P. A. Davol, S. D. Olson, J. B. Davis, K. Demel, J. Nissim, R. Rathore, P. Y. Liu, and L. G. Lum Anti-CD3 x Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model Clin. Cancer Res., January 1, 2006; 12(1): 183 - 190. [Abstract] [Full Text] [PDF]

				Y. Goto, T. Ando, H. Goto, and N. Hamajima No Association Between EGF Gene Polymorphism and Gastric Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2454 - 2456. [Abstract] [Full Text] [PDF]

				K. Dittmann, C. Mayer, B. Fehrenbacher, M. Schaller, U. Raju, L. Milas, D. J. Chen, R. Kehlbach, and H. P. Rodemann Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase J. Biol. Chem., September 2, 2005; 280(35): 31182 - 31189. [Abstract] [Full Text] [PDF]

				X. Zhang, Z. Chen, M. S. Choe, Y. Lin, S.-Y. Sun, H. S. Wieand, H. J. C. Shin, A. Chen, F. R. Khuri, and D. M. Shin Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model Clin. Cancer Res., September 1, 2005; 11(17): 6261 - 6269. [Abstract] [Full Text] [PDF]

				W. S. Siegel-Lakhai, J. H. Beijnen, and J. H.M. Schellens Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R)) Oncologist, September 1, 2005; 10(8): 579 - 589. [Abstract] [Full Text] [PDF]

				A. P. Dicker and U. Rodeck Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials J. Clin. Oncol., August 20, 2005; 23(24): 5437 - 5439. [Full Text] [PDF]

				N Andre and W Schmiegel CHEMORADIOTHERAPY FOR COLORECTAL CANCER Gut, August 1, 2005; 54(8): 1194 - 1202. [Full Text] [PDF]

				X.-T. Zhang, L.-Y. Li, X.-L. Mu, Q.-C. Cui, X.-Y. Chang, W. Song, S.-L. Wang, M.-Z. Wang, W. Zhong, and L. Zhang The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer Ann. Onc., August 1, 2005; 16(8): 1334 - 1342. [Abstract] [Full Text] [PDF]

				T. Friess, W. Scheuer, and M. Hasmann Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy Clin. Cancer Res., July 15, 2005; 11(14): 5300 - 5309. [Abstract] [Full Text] [PDF]

				J. A. Meyerhardt and R. J. Mayer Systemic Therapy for Colorectal Cancer N. Engl. J. Med., February 3, 2005; 352(5): 476 - 487. [Full Text] [PDF]

				S. Kakiuchi, Y. Daigo, N. Ishikawa, C. Furukawa, T. Tsunoda, S. Yano, K. Nakagawa, T. Tsuruo, N. Kohno, M. Fukuoka, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839) Hum. Mol. Genet., December 15, 2004; 13(24): 3029 - 3043. [Abstract] [Full Text] [PDF]

				J. H. Um, J. K. Kwon, C.-D. Kang, M. J. Kim, D. S. Ju, J. H. Bae, D. W. Kim, B. S. Chung, and S. H. Kim Relationship between Antiapoptotic Molecules and Metastatic Potency and the Involvement of DNA-Dependent Protein Kinase in the Chemosensitization of Metastatic Human Cancer Cells by Epidermal Growth Factor Receptor Blockade J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1062 - 1070. [Abstract] [Full Text] [PDF]

				N. R. Schechter, R. E. Wendt III, D. J. Yang, A. Azhdarinia, W. D. Erwin, A. M. Stachowiak, L. D. Broemeling, E. E. Kim, J. D. Cox, D. A. Podoloff, et al. Radiation Dosimetry of 99mTc-Labeled C225 in Patients with Squamous Cell Carcinoma of the Head and Neck J. Nucl. Med., October 1, 2004; 45(10): 1683 - 1687. [Abstract] [Full Text] [PDF]

				C. Buerger, K. Nagel-Wolfrum, C. Kunz, I. Wittig, K. Butz, F. Hoppe-Seyler, and B. Groner Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells J. Biol. Chem., September 26, 2003; 278(39): 37610 - 37621. [Abstract] [Full Text] [PDF]

				G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann. Onc., September 1, 2003; 14(9): 1346 - 1363. [Abstract] [Full Text] [PDF]

				E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X.-M. Zhou, W. A. Blattler, T. Chittenden, and R. Singh An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation Cancer Res., August 15, 2003; 63(16): 5073 - 5083. [Abstract] [Full Text] [PDF]

				K. A. Knuti, R. H. Wharton, K. L. Wharton, B. A. Chabner, T. J. Lynch Jr., and R. T. Penson Living as a Cancer Surpriser: A Doctor Tells His Story Oncologist, February 1, 2003; 8(1): 108 - 122. [Abstract] [Full Text] [PDF]

				R. S. Herbst and M. S. Kies ZD1839 (IressaTM) in Non-Small Cell Lung Cancer Oncologist, August 15, 2002; 7(90004): 9 - 15. [Abstract] [Full Text] [PDF]

				R. B. Natale and S. L. Zaretsky ZD1839 (IressaTM): What's in It for the Patient? Oncologist, August 15, 2002; 7(90004): 25 - 30. [Abstract] [Full Text] [PDF]